started · updated
Melanoma mRNA vaccine reduces recurrence risk by 42%
A personalized mRNA cancer vaccine has demonstrated significant success in a phase 3 clinical trial, reducing the risk of melanoma recurrence or death by 42% compared to immunotherapy alone. The trial, known as INTerpath-001, involved 1,137 patients across 157 sites globally who had undergone surgery for high-risk melanoma.
Developed by Merck and Moderna, the vaccine, named intismeran, works by analyzing the unique genetic profile of a patient's tumor to teach the immune system to recognize and attack specific cancer cells. In the study, participants received pembrolizumab (Keytruda) alongside either the personalized vaccine or a placebo. After two years, 82% of those receiving the combination therapy were alive without the cancer returning, compared to 70% in the immunotherapy-only group.
Professor Georgina Long, a lead researcher from the Melanoma Institute Australia, described the results as a foundational shift in cancer treatment, marking a milestone in personalizing immunotherapy to prevent disease relapse.
Entities
Australia · Capricorn · Georgina Long · Intismeran · Jupiter · Leo · Libra · Mars · Melanoma Institute Australia · Merck · Mercury · Moderna
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Venus is in retrograde in Libra. gyerekszoba.hu
- [○ 1 SOURCE] Aquarius, Capricorn, and Pisces may experience life turning points on this day.
- [○ 1 SOURCE] Mercury is in retrograde in Scorpio. gyerekszoba.hu
- [○ 1 SOURCE] The Sun is in Scorpio on October 28. gyerekszoba.hu
- [○ 1 SOURCE] Geminis may receive favorable financial news.
- [● 2 SOURCES] The Moon enters Gemini on October 28. gyerekszoba.hu
- [○ 1 SOURCE] The vaccine does not show additional side effects compared to immunotherapy alone. www.cittadinanzasocialenews.it
- [● 5 SOURCES] The vaccine is personalized based on the genetic profile of the patient's tumor. radiotitograd.me · www.focus.it · www.cittadinanzasocialenews.it · www.womensweekly.com.au
- [○ 1 SOURCE] The clinical trial involved 157 patients with high-risk melanoma. www.cittadinanzasocialenews.it
- [● 4 SOURCES] The vaccine is administered in combination with the immunotherapy drug pembrolizumab. www.cittadinanzasocialenews.it · www.focus.it · www.womensweekly.com.au
- [○ 1 SOURCE] The combination therapy reduced the risk of distant metastasis by 38 percent after two years. www.cittadinanzasocialenews.it
- [● 6 SOURCES] The mRNA vaccine intemneran, developed by Merck and Moderna, reduces melanoma recurrence risk by 42 percent. www.cittadinanzasocialenews.it · radiotitograd.me · www.focus.it · www.theleader.com.au · www.womensweekly.com.au